Add time:08/31/2019         Source:sciencedirect.com

In the present study, Azilsartan (AZL) was subjected to ICH recommended forced degradation conditions of hydrolysis, oxidation, dry heat and photolysis. The drug degraded to four degradation products (I–IV) under acidic, alkaline and water hydrolysis and photolysis. All the four degradation products were resolved in a single run on a C-18 column (250 mm × 4.6 mm; 5 μ) with isocratic elution using mobile phase composed of ammonium formate (20 mM, pH 3.0), methanol and acetonitrile (40:5:40% v/v), at a flow rate of 0.8 ml  min−1 at ambient temperature. The products were characterized through +ESI–MSn spectra of AZL and LC–MS–TOF studies as 2-ethoxy-3H-benzo-imidazole-4-carboxylic acid (I), 2-hydroxy-3-[2′-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid (II, deethylated AZL), 3-[2′-(1H-diazirin-3-yl)-biphenyl]-4-ylmethyl]-2-ethoxy-3H-benzoimidazole-4-carboxylic acid (III), and 3-[4′-(2-ethoxy-benzo-imidazol-1-ylmethyl)-biphenyl-2-yl]-4H-[1,2,4]oxadiazol-5-one (IV, decarboxylated AZL). Product I was found to be a known process related impurity whereas the products II–IV were identified as new degradation impurities. The most probable mechanisms for formation of these degradation products were proposed.

We also recommend Trading Suppliers and Manufacturers of Azilsartan pharMaceutical interMediate (cas 136304-78-4). Pls Click Website Link as below: cas 136304-78-4 suppliers